CDK4/6抑制剂在抗肿瘤免疫中的研究进展

Advances in Anti-tumor Immunity of CDK4/6 Inhibitors

细胞周期蛋白D(cyclin D)-细胞周期蛋白依赖性激酶4和6(CDK4/6)-神经母细胞瘤蛋白(Rb)途径在正常乳腺上皮细胞和乳腺癌细胞的增殖中起关键作用。选择性CDK4/6抑制剂(CDK4/6i)阻止Rb蛋白磷酸化,引起癌细胞在G1周期停滞。最新研究显示,CDK4/6i还可促进抗肿瘤免疫,增强免疫检查点阻断剂治疗癌症的作用,这为CDK4/6 i联合免疫疗法的新型治疗方案提供理论依据。全文重点介绍CDK4/6 i在免疫方面的影响。

The cyclin D-cyclin-dependent kinases 4 and 6(CDK4/6)-retinoblastoma(Rb) protein pathway plays a key role in the proliferation of both normal breast epithelium and breast cancer cells. Selective CDK4/6 inhibitors prevent phosphorylation of the Rb protein,invoking cancer cell cycle arrest in G1. Recent studies have demonstrated that CDK4/6 inhibitors can also promote anti-tumor immunity and augment the cancer-killing potential of checkpoint blockers,which provides a rationale for new combination regimen of CDK4/6 inhibitors with immunotherapy for cancer treatment. The immunological effects of CDK4/6 inhibitors are reviewed in this article.